Drug Discovery

Novartis to acquire anti-inflammatory drugmaker IFM Tre in $1.6bn deal

Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio.

Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe

Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part of Africa.

Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics

Boehringer Ingelheim has acquired MacroDel biologics-delivery platform developer, ICD Therapeutics, for an undisclosed amount.

AstraZeneca, Daiichi Sankyo enter into $6.9bn cancer deal

Major drugmaker AstraZeneca has entered into a $6.9bn cancer deal with Japanese pharmaceutical firm Daiichi Sankyo.

Cancer Research UK, LifeArc, Ono Pharma establish new drug discovery alliance

Cancer Research UK has entered into a multi-year partnership with LifeArc and Ono Pharmaceutical to identify new immunotherapy drug targets for cancer.

MedPharm to develop new XF-drug formulations

Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF‐platform compounds.

Transgene, BioInvent extend collaboration to develop multifunctional oncolytic viruses for solid tumors

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB, a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.

Arch Oncology raises $50m Series B financing

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing.

Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn

Thermo Fisher Scientific has agreed to acquire viral vector contract development and manufacturing organization (CDMO), Brammer Bio, for around $1.7bn in cash.